Skip to main content

CASE REPORT article

Front. Oncol.
Sec. Gastrointestinal Cancers: Colorectal Cancer
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1473620
This article is part of the Research Topic New Approaches, Concepts and Treatments in Gastrointestinal and Surgical Oncology View all 4 articles

A case report of HER2-positive descending colon cancer with peritoneal metastasis and literature review

Provisionally accepted
lv yaochun lv yaochun 1QIAN ZHENGPENG QIAN ZHENGPENG 2,3wu dewang wu dewang 1zhu chengzhang zhu chengzhang 4zhang jipeng zhang jipeng 2ning yeping ning yeping 2Binbin Du Binbin Du 1,4*
  • 1 Clinical Medical Research Center for Anorectal Diseases of Gansu Province, lanzhou, China
  • 2 The First Clinical Medical College, Gansu University of Chinese Medicine, Lanzhou, Gansu Province, China
  • 3 Clinical Medical Research Center for Anorectal Diseases of Gansu Province, Gansu Provincial Hospital, Lanzhou, China
  • 4 Lanzhou University, Lanzhou, Gansu Province, China

The final, formatted version of the article will be published soon.

    Human epidermal growth factor receptor 2 (HER2) is an anti-cancer drug target for colon cancer. Among patients with colorectal malignancy (colorectal cancer, CRC), those with HER2 mutations have a poor overall prognosis and a significantly increased drug resistance. In recent years, anti-HER2 therapeutic drugs have developed rapidly. According to several clinical studies and case reports, anti-HER2 therapy, as an emerging anti-cancer approach, plays a crucial role in the treatment of HER2-positive CRC patients. Here, we present a case of HER2-positive descending colon cancer with peritoneal metastasis. The patient is a 26-year-old male, diagnosed with malignant tumor of the descending colon with peritoneal metastasis in April 2020. After multiple treatment modalities, the disease progressed. After chemotherapy with Trastuzumab Deruxtecan (T-DXd/DS-8201), the metastatic foci significantly shrank, and after surgical resection, a tumor-free state (NED) was achieved. Up to now, the patient's survival period has reached 56 months.

    Keywords: HER2-positive descending colon cancer, Peritoneal metastasis, Anti-HER2 therapy, Multidisciplinary Collaboration (MDT), case report

    Received: 31 Jul 2024; Accepted: 05 Feb 2025.

    Copyright: © 2025 yaochun, ZHENGPENG, dewang, chengzhang, jipeng, yeping and Du. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Binbin Du, Clinical Medical Research Center for Anorectal Diseases of Gansu Province, lanzhou, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.